Echinacoside是一种从Cistanche tubulosa中分离的，具有强效抗氧化和抗炎作用的苯乙醇类化合物。
Cas No.:82854-37-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Echinacoside is a phenylethanoid glycoside isolated from Cistanche tubulosa with potent antioxidant and anti-inflammatory effects[1]. Echinacoside is commonly used in research on neurodegenerative diseases (Parkinson's disease, Alzheimer's disease), cardiovascular health, and skin protective agents[2,3,4].
In vitro, Echinacoside (20, 50, 100μg/mL) treatment of HepG2 cells for 24, 48, and 72h inhibited cell proliferation in a concentration- and time-dependent manner and induced apoptosis. Echinacoside (50, 100μg/mL) treatment of HepG2 cells for 48h significantly reduced p-AKT protein levels and upregulated the protein expression of p21 and Bax[5]. Echinacoside (0.1, 1, 10nM) treatment of MC3T3-E1 cells for 21 days dose-dependently and significantly promoted mineralized nodule formation[6].
In vivo, intragastric administration of Echinacoside (30, 90, 270mg/kg/day) to ovariectomized rats for 12 weeks significantly increased osteoprotegerin levels and decreased receptor activator of nuclear factor-κB ligand (RANKL) levels[7]. A single oral dose of Echinacoside (250, 500mg/kg) administered to starch-loaded mice significantly inhibited the postprandial increase in blood glucose levels, with blood glucose levels in the 500mg/kg dose group being significantly lower than those in the control group at 0.5, 1, and 2h[8].
References:
[1] LIU J, YANG L, DONG Y, et al. Echinacoside, an inestimable natural product in treatment of neurological and other disorders[J]. Molecules, 2018, 23(5): 1213.
[2] LI J, YU H, YANG C, et al. Therapeutic potential and molecular mechanisms of echinacoside in neurodegenerative diseases[J]. Frontiers in Pharmacology, 2022, 13: 841110.
[3] SHEOKAND A, KOLI D, WADHWA K, et al. Mechanistic insights into the anticancer potential of echinacoside: therapeutic applications and future directions[J]. Archiv der Pharmazie, 2025, 358(11): e70153.
[4] LI L, RAN Y, WEN J, et al. Traditional Chinese medicine-based treatment in cardiovascular disease: potential mechanisms of action[J]. Current Pharmaceutical Biotechnology, 2024, 25(17): 2186-2199.
[5] YE Y, SONG Y, ZHUANG J, et al. Anticancer effects of echinacoside in hepatocellular carcinoma mouse model and HepG2 cells[J]. Journal of Cellular Physiology, 2019, 234(2): 1880-1888.
[6] LI F, YANG Y, ZHU P, et al. Echinacoside promotes bone regeneration by increasing OPG/RANKL ratio in MC3T3-E1 cells[J]. Fitoterapia, 2012, 83(8): 1443-1450.
[7] WU L, GEORGIEV M I, CAO H, et al. Therapeutic potential of phenylethanoid glycosides: a systematic review[J]. Medicinal Research Reviews, 2020, 40(6): 2605-2649.
[8] MORIKAWA T, NINOMIYA K, IMAMURA M, et al. Acylated phenylethanoid glycosides, echinacoside and acteoside from Cistanche tubulosa, improve glucose tolerance in mice[J]. Journal of Natural Medicines, 2014, 68(3): 561-566.
Echinacoside是一种从Cistanche tubulosa中分离的，具有强效抗氧化和抗炎作用的苯乙醇类化合物[1]。Echinacoside通常用于神经退行性疾病（帕金森病、阿尔茨海默病）、心血管健康及皮肤保护剂的研究[2,3,4]。
在体外，Echinacoside（20, 50, 100μg/mL）处理HepG2细胞24、48和72h，可浓度和时间依赖性地抑制细胞增殖，并诱导细胞凋亡。Echinacoside（50, 100μg/mL）处理HepG2细胞48h，可显著降低p-AKT蛋白水平，并上调p21和Bax的蛋白表达[5]。Echinacoside（0.1, 1, 10nM）处理MC3T3-E1细胞21天，可剂量依赖性地显著促进矿化结节形成[6]。
在体内，Echinacoside（30, 90, 270mg/kg/day）通过灌胃治疗去卵巢大鼠12周，可显著提高骨保护素水平，降低核因子κB受体活化因子配体（RANKL）水平[7]。Echinacoside（250, 500mg/kg）通过口服单次给予淀粉负荷小鼠，可显著抑制餐后血糖升高，其中500mg/kg剂量在0.5h、1h和2h的血糖水平均显著低于对照组[8]。
| Cell experiment [1]: | |
Cell lines | HepG2 cells |
Preparation Method | HepG2 cells were exposed to various doses of Echinacoside (50, 100μg/mL). After 48h, the western blot analysis was performed to assess the expression of p‐AKT, p21, and Bax. |
Reaction Conditions | 50, 100μg/mL; 48h |
Applications | Treatment of Echinacoside significantly reduced p-AKT protein levels and upregulated p21 and Bax protein expression. |
| Animal experiment [2]: | |
Animal models | Starch-loaded ddY mice |
Preparation Method | A mixture of Echinacoside (250, 500mg/kg) and α-starch (1g/kg) suspended in 5% (w/v) acacia solution was administered orally to fasted mice. Blood samples were collected from the infraorbital venous plexus under ether anesthesia at 0.5, 1, and 2h after oral administration, and plasma glucose levels were determined enzymatically by the Glucose CII test Wako. |
Dosage form | 250, 500mg/kg; p.o. |
Applications | Treatment of Echinacoside significantly inhibited the rise in postprandial blood glucose in starch-loaded mice, with blood glucose levels at 0.5h, 1h, and 2h significantly lower than those in the control group at a dose of 500mg/kg. |
References: | |
| Cas No. | 82854-37-3 | SDF | |
| 别名 | 松果菊苷 | ||
| 化学名 | [(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate | ||
| Canonical SMILES | CC1C(C(C(C(O1)OC2C(C(OC(C2OC(=O)C=CC3=CC(=C(C=C3)O)O)COC4C(C(C(C(O4)CO)O)O)O)OCCC5=CC(=C(C=C5)O)O)O)O)O)O | ||
| 分子式 | C35H46O20 | 分子量 | 786.72 |
| 溶解度 | ≥ 78.7mg/mL in DMSO | 储存条件 | Store at 2-8°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2711 mL | 6.3555 mL | 12.711 mL |
| 5 mM | 254.2 μL | 1.2711 mL | 2.5422 mL |
| 10 mM | 127.1 μL | 635.6 μL | 1.2711 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet